2021; Uebergang et al. 2023) and plays an important role in AD pathological processes (Haney et al. 2024; Montagne et al. 2020; Blanchard et al. 2022). By age 85, the lifetime risk for AD in APOE ε4 homozygotes reaches 60%, and heterozygotes exhibit semi‐dominant effects of this moderately penetrant gene (Fortea 2024; Genin et al. 2011). However, the mechanism by which the APOE ε4 allele mediates AD pathology remains incompletely understood. Therefore, exploring the underlying pathogenesis of the APOE ε4 allele may provide new therapeutic opportunities for AD patients. This evidence concerns the gene APOE and Alzheimer disease.